Literature DB >> 7317244

Reduction of venous sequelae of i.v. diazepam with a fat emulsion as solvent.

M A Mattila, M L Rossi, M K Ruoppi, M Korhonen, H M Larni, S Kortelainen.   

Abstract

Venous sequelae were studied in 93 female patients undergoing minor gynaecological procedures. They were premedicated with diazepam i. v. dissolved in a fat emulsion (Diazemuls) injected to a superficial vein of the right hand. The patients observed the site of injection for 14 days and recorded their findings. Twenty-eight per cent reported mild tenderness and 7.5% mild or moderate swelling of short duration. Signs of thrombophlebitis were found in 2.2%. Thrombophlebitis after injection can be prevented effectively and safely using fat emulsion as a solvent for diazepam.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7317244     DOI: 10.1093/bja/53.12.1265

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  4 in total

1.  Side-effect evaluation of a new diazepam formulation: venous sequela reduction following intravenous (i.v.) injection of a diazepam emulsion in rabbits.

Authors:  M Y Levy; L Langerman; S Gottschalk-Sabag; S Benita
Journal:  Pharm Res       Date:  1989-06       Impact factor: 4.200

2.  Effect of aging on anticonflict and CNS depressant activity of diazepam in rats.

Authors:  H L Komiskey; M A Buck; K L Mundinger; F K McSweeney; V A Farmer-Dougan; J D Dougan
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

3.  Bioequivalence and tolerability assessment of a novel intravenous ciclosporin lipid emulsion compared to branded ciclosporin in Cremophor ® EL.

Authors:  Karl Henrik Johannes Ehinger; Magnus Joakim Hansson; Fredrik Sjövall; Eskil Elmér
Journal:  Clin Drug Investig       Date:  2013-01       Impact factor: 2.859

4.  Transdermal glyceryl trinitrate to allow peripheral total parenteral nutrition: a double-blind placebo controlled feasibility study.

Authors:  H T Khawaja; J D Williams; P C Weaver
Journal:  J R Soc Med       Date:  1991-02       Impact factor: 18.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.